Progerin, an Aberrant Spliced Form of Lamin A, Is a Potential Therapeutic Target for HGPS

• Published in: Cells (Basel, Switzerland) Switzerland), 2023-09, Vol.12 (18), p.2299
• Main Authors: Kim, Bae-Hoon, Chung, Yeon-Ho, Woo, Tae-Gyun, Kang, So-Mi, Park, Soyoung, Park, Bum-Joon
• Format: Article
• Language: English
• Subjects: Aging; Amino acids; Clinical trials; Cognition; Disease; DNA damage; DNA methylation; Drug targeting; Drug therapy; Fibroblasts; Gene expression; Genetic disorders; Genotype & phenotype; Health aspects; Hutchinson–Gilford progeria syndrome; Intermediate filament proteins; Methods; Mutation; Neurological diseases; nuclear lamina; Patients; Progeria; progerin; Proteins; Quality of life; Review; Senescence; Telomerase; Therapeutic targets
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12182299

Hutchinson–Gilford progeria syndrome (HGPS) is an extremely rare genetic disorder caused by the mutant protein progerin, which is expressed by the abnormal splicing of the LMNA gene. HGPS affects systemic levels, with the exception of cognition or brain development, in children, showing that cellular aging can occur in the short term. Studying progeria could be useful in unraveling the causes of human aging (as well as fatal age-related disorders). Elucidating the clear cause of HGPS or the development of a therapeutic medicine could improve the quality of life and extend the survival of patients. This review aimed to (i) briefly describe how progerin was discovered as the causative agent of HGPS, (ii) elucidate the puzzling observation of the absence of primary neurological disease in HGPS, (iii) present several studies showing the deleterious effects of progerin and the beneficial effects of its inhibition, and (iv) summarize research to develop a therapy for HGPS and introduce clinical trials for its treatment.